8月24日，恒瑞医药盘中下跌3.03%，报46.74港元，成交额3.26亿港元。
消息面上，交银国际当日发布研报，下调恒瑞医药DCF目标价至57港元，指出存量品种或持续承压，维持中性评级。该机构认为公司仿制药收入受地方集采影响同比下滑16%，肿瘤创新药增速放缓至2.6%，成熟品种竞争加剧及竞品集采降价构成压力，当前估值合理但后续潜在升幅有限。
此前公司披露半年报显示，营收154.56亿元同比下降1.94%，扣非归母净利润37.30亿元同比大幅下滑12.71%，经营活动现金流净额同比骤降53.8%，主业盈利质量明显承压，股价已连续多日走弱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.